A number of firms have modified their ratings and price targets on shares of Inovio Pharmaceuticals (NASDAQ: INO) recently:

  • 11/13/2017 – Inovio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Inovio reported wider-than-expected loss in the third quarter of 2017 with revenue missing estimates. As the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Meanwhile highly lucrative immuno-oncology market has been the focus area of several big pharma giants which may pose intense competition to the candidates once approved. Shares of the company have underperformed the industry so far this year. However, we are positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging.”
  • 11/9/2017 – Inovio Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 11/9/2017 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
  • 10/27/2017 – Inovio Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/25/2017 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/18/2017 – Inovio Pharmaceuticals is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $11.00 price target on the stock.
  • 10/17/2017 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/13/2017 – Inovio Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/10/2017 – Inovio Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Inovio has a collaboration agreement with several companies and institutes like big pharma companies Roche, AstraZeneca, and the University of Pennsylvania, which not only lend it their expertise but also provide the required funding for development of its pipeline candidates. Also, the company’s progress with its pipeline is impressive. Nonetheless, the company’s targeted cervical cancer market holds huge untapped potential. The initiation of phase III program on its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. However, due to the early/mid-stage nature of Inovio’s pipeline, the company is highly dependent on VGX-3100, which is concerning. Shares of the company have underperformed the industry so far this year.”
  • 10/6/2017 – Inovio Pharmaceuticals was given a new $13.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/6/2017 – Inovio Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $10.00 price target on the stock.
  • 9/22/2017 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
  • 9/18/2017 – Inovio Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Inovio Pharmaceuticals, Inc. (INO) opened at $4.55 on Tuesday. Inovio Pharmaceuticals, Inc. has a one year low of $4.40 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business’s quarterly revenue was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.28) earnings per share. research analysts predict that Inovio Pharmaceuticals, Inc. will post -1.08 EPS for the current year.

The business also recently announced a monthly dividend, which was paid on Monday, October 16th. Shareholders of record on Friday, September 29th were paid a $0.069 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 18.20%. The ex-dividend date was Thursday, September 28th.

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.